Ustekinumab and low-dose Upadacitinib combination therapy in medically difficult-to-treat patients with Crohn's disease (ChiCTR) - Oct 16, 2026 - P=N/A | N=84 | Completed | Sponsor: Department of Gastroenterology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China; Department of Gastroe
New trial • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • CRP
|